Shares of Hims & Hers Health plunged Friday after the Food & Drug Administration said a shortage of the active ingredient in ...

Shares of Hims & Hers Health ( HIMS -24.30%) are falling on Friday. The company's stock lost 23.2% as of 1 p.m. ET and lost ...

The ruling shows Novo Nordisk’s confidence that the supply of semaglutide will be stable for now.

The telehealth company has been selling a copycat version of a popular obesity drug during the recent shortage.

UnitedHealth declines following a report that the Justice Department has been investigating the company’s Medicare billing ...

Semaglutide is a glucagon-like peptide-1 (GLP-1) that helps regulate blood sugar levels. Because of outsized demand for ...

Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...

Leerink notes that the shortage of Novo Nordisk’s (NVO) semaglutide, marketed as Wegovy and Ozempic, has been resolved according to the FDA.

The U.S. FDA declared that Novo Nordisk's weight loss and diabetes drugs, Ozempic and Wegovy, are no longer in shortage.

Shares tumbled 21% to $52.22. Over the last year, the stock has surged more than 450%.

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 24% in the afternoon session after U.S. Food and Drug Administration (FDA) reported that the shortage of weight-loss drugs such as ...